Feb. 2 at 11:41 AM
Citizens reiterated
$KURA Market Outperform-
$24 and said, We reiterate our Market Outperform rating and price target of
$24 for Kura Oncology based on a discounted EPS and revenue multiple analysis.
$SNDX $RIGL $CGEM
Citizens added, Earlier this month, Kura provided an outlook for 2026, including an update on its (very early) KOMZIFTI launch and key milestones for its FTI program and next-gen menin inhibitor pipeline.
The presentation showcased Kura's aggressive approach to cornering the ~
$7B AML market, and comparison to competitor Syndax suggests Kura may take an incrementally larger share in the long run.
With a first approval and commercialization underway, the frontline AML trials fully funded, the FTI program making progress through the clinic, and a pro forma cash position of
$667.3MM, we believe Kura shares represent an attractive investment opportunity.
